CERO THERAPEUTICS HOLDINGS INC
For the period ended Dec 31, 2023. Filed Apr 2, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 2, 2024
CERO$0.00-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| OPERATING EXPENSES | ||
| General and administrative | $2,892,935 | $2,841,391 |
| Franchise tax | 40,050 | 64,050 |
| Loss from operations | (2,932,985) | (2,905,441) |
| Other income: | ||
| Interest income earned on marketable securities held in Trust Account | 491,571 | 2,836,864 |
| Total other income | 491,571 | 2,836,864 |
| Loss before provision for income taxes | (2,441,414) | (68,577) |
| Provision for income taxes | (94,819) | (599,159) |
| Net loss | $(2,536,233) | $(667,736) |
| Weighted average shares outstanding of Class A common stock | 4,224,247 | 17,896,428 |
| Basic and diluted net loss per share, Class A common stock | $(0.39) | $(0.03) |
| Weighted average shares outstanding of Class B common stock | 2,304,421 | 4,596,250 |
| Basic and diluted net loss per share, Class B common stock | $(0.39) | $(0.03) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.